** Shares of drug developer Soleno Therapeutics SLNO.O fall ~6% to $54 premarket
** Co says U.S. FDA has extended review of its experimental drug to treat Prader–Willi syndrome, a rare genetic disorder
** The condition causes affected individuals to develop extreme hunger, which leads to chronic overeating, or hyperphagia, and obesity
** FDA determined that co's responses to recent information requests constituted major amendment to marketing application for the drug, diazoxide choline extended-release tablets
** The health regulator will now give its decision by March 27, 2025, compared with its previous action date of Dec. 27 this year
** FDA did not cite any safety, efficacy or manufacturing concerns, SLNO says
** Up to last close, stock up ~42% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。